Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

A non-lethal malarial infection results in reduced drug metabolizing enzyme expression and drug clearance in mice.

Mimche SM, Lee CM, Liu KH, Mimche PN, Harvey RD, Murphy TJ, Nyagode BA, Jones DP, Lamb TJ, Morgan ET.

Malar J. 2019 Jul 12;18(1):234. doi: 10.1186/s12936-019-2860-5.

2.

Effect of Adenylyl Cyclase Type 6 on Localized Production of cAMP by β-2 Adrenoceptors in Human Airway Smooth-Muscle Cells.

Agarwal SR, Fiore C, Miyashiro K, Ostrom RS, Harvey RD.

J Pharmacol Exp Ther. 2019 Jul;370(1):104-110. doi: 10.1124/jpet.119.256594. Epub 2019 May 8.

PMID:
31068382
3.

Safety of Intranasal Ketamine for Reducing Uncontrolled Cancer-Related Pain: Protocol of a Phase I/II Clinical Trial.

Shteamer JW, Harvey RD, Spektor B, Curseen K, Egan K, Chen Z, Gillespie TW, Sniecinski RM, Singh V.

JMIR Res Protoc. 2019 Apr 30;8(4):e12125. doi: 10.2196/12125.

4.

Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies.

Harvey RD, Zhang C, Lonial S, Kaufman JL, Chen Z.

Cancer. 2019 Mar 28. doi: 10.1002/cncr.32080. [Epub ahead of print] No abstract available.

PMID:
30919409
5.

Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment.

Grande E, Harvey RD, You B, Batlle JF, Galbraith H, Sarantopoulos J, Ramalingam SS, Mann H, So K, Johnson M, Vishwanathan K.

J Pharmacol Exp Ther. 2019 May;369(2):291-299. doi: 10.1124/jpet.118.255919. Epub 2019 Mar 14.

PMID:
30872388
6.

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.

Faessel H, Nemunaitis J, Bauer TM, Lockhart AC, Faller DV, Sedarati F, Zhou X, Venkatakrishnan K, Harvey RD.

Br J Clin Pharmacol. 2019 Jul;85(7):1464-1473. doi: 10.1111/bcp.13915. Epub 2019 May 17.

7.

Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.

Saba NF, Force S, Staley C, Fernandez F, Willingham F, Pickens A, Cardona K, Chen Z, Goff L, Cardin D, Lambright E, Nesbitt J, Krasinskas A, Higgins K, Harvey RD, Owonikoko T, Ramalingam SS, Shin DM, Beitler JJ, El-Rayes BF, Salaria S, El-Rifai W, Landry J, Chakravarthy AB.

Am J Clin Oncol. 2019 Apr;42(4):331-336. doi: 10.1097/COC.0000000000000524.

PMID:
30789414
8.

Managing Drug Interactions With Oral Anticancer Agents: Signals, Noise, and Echoes.

Harvey RD.

J Oncol Pract. 2019 Feb;15(2):91-92. doi: 10.1200/JOP.18.00721. No abstract available.

PMID:
30763201
9.

Reply to Tumor-associated macrophages: "Good cop-bad cop".

Bilen MA, Kissick HT, Harvey RD.

Cancer. 2019 Jun 1;125(11):1942-1943. doi: 10.1002/cncr.32015. Epub 2019 Feb 12. No abstract available.

PMID:
30748009
10.

Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.

Martini DJ, Liu Y, Shabto JM, Lewis C, Kline MR, Collins H, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, Master VA, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Bilen MA.

Invest New Drugs. 2019 Feb 6. doi: 10.1007/s10637-019-00736-0. [Epub ahead of print]

PMID:
30725388
11.

Academic oncology clinicians' understanding of biosimilars and information needed before prescribing.

Cook JW, McGrath MK, Dixon MD, Switchenko JM, Harvey RD, Pentz RD.

Ther Adv Med Oncol. 2019 Jan 6;11:1758835918818335. doi: 10.1177/1758835918818335. eCollection 2019.

12.

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.

Kaufman JL, Mina R, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, Gleason C, Sharp C, Martin T, Heffner LT, Nooka AK, Harvey RD, Lonial S.

Blood Cancer J. 2019 Jan 4;9(1):3. doi: 10.1038/s41408-018-0154-8.

13.

The pH-dependence of lipid-mediated antimicrobial peptide resistance in a model staphylococcal plasma membrane: A two-for-one mechanism of epithelial defence circumvention.

Rehal R, Gaffney PRJ, Hubbard ATM, Barker RD, Harvey RD.

Eur J Pharm Sci. 2019 Feb 1;128:43-53. doi: 10.1016/j.ejps.2018.11.017. Epub 2018 Nov 22.

PMID:
30471412
14.

Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.

Ou Y, Xu Y, Gore L, Harvey RD, Mita A, Papadopoulos KP, Wang Z, Cutler RE Jr, Pinchasik DE, Tsimberidou AM.

Br J Clin Pharmacol. 2019 Mar;85(3):530-539. doi: 10.1111/bcp.13817. Epub 2018 Dec 25.

PMID:
30428505
15.

Tolerance of MRSA ST239-TW to chlorhexidine-based decolonization: Evidence for keratinocyte invasion as a mechanism of biocide evasion.

Marbach H, Vizcay-Barrena G, Memarzadeh K, Otter JA, Pathak S, Allaker RP, Harvey RD, Edgeworth JD.

J Infect. 2019 Feb;78(2):119-126. doi: 10.1016/j.jinf.2018.10.007. Epub 2018 Oct 24.

PMID:
30367885
16.

The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.

Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Master VA, Ramalingam SS, Owonikoko TK, Harvey RD.

Cancer. 2019 Jan 1;125(1):127-134. doi: 10.1002/cncr.31778. Epub 2018 Oct 17.

PMID:
30329148
17.

Diminishing biofilm resistance to antimicrobial nanomaterials through electrolyte screening of electrostatic interactions.

Harper RA, Carpenter GH, Proctor GB, Harvey RD, Gambogi RJ, Geonnotti AR, Hider R, Jones SA.

Colloids Surf B Biointerfaces. 2019 Jan 1;173:392-399. doi: 10.1016/j.colsurfb.2018.09.018. Epub 2018 Sep 12.

18.

Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.

Chehab S, Zhang C, Panjic EH, Chen Z, Kaufman JL, Lonial S, Nooka A, Harvey RD.

Cancer. 2018 Nov 15;124(22):4358-4365. doi: 10.1002/cncr.31746. Epub 2018 Oct 10.

PMID:
30303526
19.

Design and development of a biorelevant simulated human lung fluid.

Hassoun M, Royall PG, Parry M, Harvey RD, Forbes B.

J Drug Deliv Sci Technol. 2018 Oct;47:485-491. doi: 10.1016/j.jddst.2018.08.006.

20.

Accelerating anticancer drug development - opportunities and trade-offs.

Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, Harvey RD, Piantadosi S, Bertagnolli MM, Schrag D, Schilsky RL.

Nat Rev Clin Oncol. 2018 Dec;15(12):777-786. doi: 10.1038/s41571-018-0102-3. Review.

PMID:
30275514
21.

Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.

Harvey RD, Aransay NR, Isambert N, Lee JS, Arkenau T, Vansteenkiste J, Dickinson PA, Bui K, Weilert D, So K, Thomas K, Vishwanathan K.

Br J Clin Pharmacol. 2018 Dec;84(12):2877-2888. doi: 10.1111/bcp.13753. Epub 2018 Oct 10.

PMID:
30171779
22.

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.

Gupta N, Hanley MJ, Xia C, Labotka R, Harvey RD, Venkatakrishnan K.

Clin Pharmacokinet. 2019 Apr;58(4):431-449. doi: 10.1007/s40262-018-0702-1. Review.

23.

Rationale, Opportunities, and Reality of Biosimilar Medications.

Lyman GH, Zon R, Harvey RD.

N Engl J Med. 2018 Aug 16;379(7):694-695. doi: 10.1056/NEJMc1808348. No abstract available.

PMID:
30110587
24.

Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.

Moore DC, Arnall JR, Harvey RD.

J Oncol Pharm Pract. 2019 Apr;25(3):613-622. doi: 10.1177/1078155218788706. Epub 2018 Jul 31. Review.

PMID:
30060709
25.

Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials.

Owonikoko TK, Busari AK, Kim S, Chen Z, Akintayo A, Lewis C, Carthon BC, Alese OB, El-Rayes BF, Ramalingam SS, Harvey RD.

Oncology. 2018;95(3):138-146. doi: 10.1159/000488763. Epub 2018 Jun 18.

26.

Reply to S.D. Lucio.

Lyman GH, Zon R, Harvey RD, Schilsky RL.

J Clin Oncol. 2018 Jul 10;36(20):2127. doi: 10.1200/JCO.2018.79.1780. Epub 2018 May 30. No abstract available.

PMID:
29847292
27.

A combined FTIR and DSC study on the bilayer-stabilising effect of electrostatic interactions in ion paired lipids.

Schmid M, Wölk C, Giselbrecht J, Chan KLA, Harvey RD.

Colloids Surf B Biointerfaces. 2018 Sep 1;169:298-304. doi: 10.1016/j.colsurfb.2018.05.031. Epub 2018 May 17.

PMID:
29793092
28.

Rationale, Opportunities, and Reality of Biosimilar Medications.

Lyman GH, Zon R, Harvey RD, Schilsky RL.

N Engl J Med. 2018 May 24;378(21):2036-2044. doi: 10.1056/NEJMhle1800125. No abstract available.

PMID:
29791832
29.

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.

Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A.

Invest New Drugs. 2019 Feb;37(1):87-97. doi: 10.1007/s10637-018-0610-0. Epub 2018 May 21.

30.

Compartmentalized cAMP Signaling Associated With Lipid Raft and Non-raft Membrane Domains in Adult Ventricular Myocytes.

Agarwal SR, Gratwohl J, Cozad M, Yang PC, Clancy CE, Harvey RD.

Front Pharmacol. 2018 Apr 23;9:332. doi: 10.3389/fphar.2018.00332. eCollection 2018.

31.

Glycerol Solvates DPPC Headgroups and Localizes in the Interfacial Regions of Model Pulmonary Interfaces Altering Bilayer Structure.

Terakosolphan W, Trick JL, Royall PG, Rogers SE, Lamberti O, Lorenz CD, Forbes B, Harvey RD.

Langmuir. 2018 Jun 12;34(23):6941-6954. doi: 10.1021/acs.langmuir.8b00866. Epub 2018 May 30.

PMID:
29738253
32.

Influence of the Surfactant Structure on Photoluminescent π-Conjugated Polymer Nanoparticles: Interfacial Properties and Protein Binding.

Urbano L, Clifton L, Ku HK, Kendall-Troughton H, Vandera KA, Matarese BFE, Abelha T, Li P, Desai T, Dreiss CA, Barker RD, Green MA, Dailey LA, Harvey RD.

Langmuir. 2018 May 29;34(21):6125-6137. doi: 10.1021/acs.langmuir.8b00561. Epub 2018 May 17.

PMID:
29726688
33.

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28.

34.

American Society of Clinical Oncology Statement: Biosimilars in Oncology.

Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL.

J Clin Oncol. 2018 Apr 20;36(12):1260-1265. doi: 10.1200/JCO.2017.77.4893. Epub 2018 Feb 14.

PMID:
29443651
35.

Soft, adhesive (+) alpha tocopherol phosphate planar bilayers that control oral biofilm growth through a substantive antimicrobial effect.

Harper RA, Saleh MM, Carpenter G, Abbate V, Proctor G, Harvey RD, Gambogi RJ, Geonnotti A, Hider R, Jones SA.

Nanomedicine. 2018 Oct;14(7):2307-2316. doi: 10.1016/j.nano.2017.12.024. Epub 2018 Feb 2.

36.

Intranasal Ketamine and Its Potential Role in Cancer-Related Pain.

Singh V, Gillespie TW, Harvey RD.

Pharmacotherapy. 2018 Mar;38(3):390-401. doi: 10.1002/phar.2090. Epub 2018 Feb 23. Review.

PMID:
29396996
37.

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.

Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, Dingemans AC, Kim HR, Kim JH, Krebs MG, Chih-Hsin Yang J, Bui K, Weilert D, Harvey RD.

Br J Clin Pharmacol. 2018 Jun;84(6):1156-1169. doi: 10.1111/bcp.13534. Epub 2018 Mar 23.

38.

cAMP Signaling Compartmentation: Adenylyl Cyclases as Anchors of Dynamic Signaling Complexes.

Johnstone TB, Agarwal SR, Harvey RD, Ostrom RS.

Mol Pharmacol. 2018 Apr;93(4):270-276. doi: 10.1124/mol.117.110825. Epub 2017 Dec 7. Review.

39.

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.

Papadopoulos KP, El-Rayes BF, Tolcher AW, Patnaik A, Rasco DW, Harvey RD, LoRusso PM, Sachdev JC, Abbadessa G, Savage RE, Hall T, Schwartz B, Wang Y, Kazakin J, Shaib WL.

Br J Cancer. 2017 Nov 21;117(11):1592-1599. doi: 10.1038/bjc.2017.330. Epub 2017 Oct 3.

40.

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group.

Lichtman SM, Harvey RD, Damiette Smit MA, Rahman A, Thompson MA, Roach N, Schenkel C, Bruinooge SS, Cortazar P, Walker D, Fehrenbacher L.

J Clin Oncol. 2017 Nov 20;35(33):3753-3759. doi: 10.1200/JCO.2017.74.4102. Epub 2017 Oct 2.

PMID:
28968172
41.

Science of Biosimilars.

Harvey RD.

J Oncol Pract. 2017 Sep;13(9_suppl):17s-23s. doi: 10.1200/JOP.2017.026062. Review.

PMID:
28898589
42.

Comparing the action of HT61 and chlorhexidine on natural and model Staphylococcus aureus membranes.

Hubbard AT, Coates AR, Harvey RD.

J Antibiot (Tokyo). 2017 Oct;70(10):1020-1025. doi: 10.1038/ja.2017.90. Epub 2017 Aug 2.

PMID:
28765589
43.

The influence of mild acidity on lysyl-phosphatidylglycerol biosynthesis and lipid membrane physico-chemical properties in methicillin-resistant Staphylococcus aureus.

Rehal RP, Marbach H, Hubbard ATM, Sacranie AA, Sebastiani F, Fragneto G, Harvey RD.

Chem Phys Lipids. 2017 Aug;206:60-70. doi: 10.1016/j.chemphyslip.2017.06.007. Epub 2017 Jun 23.

PMID:
28648851
44.

Compartmentalized cAMP responses to prostaglandin EP2 receptor activation in human airway smooth muscle cells.

Agarwal SR, Miyashiro K, Latt H, Ostrom RS, Harvey RD.

Br J Pharmacol. 2017 Aug;174(16):2784-2796. doi: 10.1111/bph.13904. Epub 2017 Jul 12.

45.

A multiscale computational modelling approach predicts mechanisms of female sex risk in the setting of arousal-induced arrhythmias.

Yang PC, Perissinotti LL, López-Redondo F, Wang Y, DeMarco KR, Jeng MT, Vorobyov I, Harvey RD, Kurokawa J, Noskov SY, Clancy CE.

J Physiol. 2017 Jul 15;595(14):4695-4723. doi: 10.1113/JP273142. Epub 2017 Jun 14.

46.

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.

Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, Harvey RD, Venkatakrishnan K.

Clin Pharmacokinet. 2017 Nov;56(11):1355-1368. doi: 10.1007/s40262-017-0526-4.

47.

Mechanism of Action of a Membrane-Active Quinoline-Based Antimicrobial on Natural and Model Bacterial Membranes.

Hubbard AT, Barker R, Rehal R, Vandera KA, Harvey RD, Coates AR.

Biochemistry. 2017 Feb 28;56(8):1163-1174. doi: 10.1021/acs.biochem.6b01135. Epub 2017 Feb 13.

PMID:
28156093
48.

A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.

Wu B, Lewis LD, Harvey RD, Rasmussen E, Gamelin E, Sun YN, Friberg G, Koyner JL, Dowlati A, Maitland ML.

Clin Pharmacol Ther. 2017 Aug;102(2):313-320. doi: 10.1002/cpt.617. Epub 2017 Jun 9.

PMID:
28074547
49.

Precision, accuracy, and resolution-Dose selection of oral anticancer agents.

Beardslee TJ, Harvey RD.

Cancer. 2016 Nov 15;122(22):3424-3427. doi: 10.1002/cncr.30273. Epub 2016 Aug 15. No abstract available.

50.

Preventing and Managing Toxicities of High-Dose Methotrexate.

Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD.

Oncologist. 2016 Dec;21(12):1471-1482. Epub 2016 Aug 5. Review.

Supplemental Content

Loading ...
Support Center